ChartAlert®

Featured

Hello, India!

This featured post is about ChartAlert, a Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software

1–2 minutes

ChartAlert® is a Microsoft® Windows® compatible Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software that complements your trading and investing needs.

ChartAlert features three seamless modules.

1. The Charting module includes Charting and Masks.

2. The Reporting module includes Basic Advisory Content and Market Reports.

3. The Scanning module includes Basic Scanner, Advanced Scanner, RS Matrix & Trend Matrix, Trading Systems Builder and the Backtester.

ASIANPAINT – Asian Paints – Q4 FY26 Financial Results – 29-May-26

Asian Paints’ FY26 delivered margin recovery and record FCF despite just 5% topline growth. Q4 re‑acceleration is positive, but re‑rating hinges on H1FY27 volume growth >8–10% as Birla Opus disruption stabilises. Home décor losses narrowing and international profitability doubling are tailwinds; monitor Q1 volumes and receivables.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 5.0% YoY (₹33,906 Cr → ₹35,584 Cr FY26); Q4 alone surged 10.6% YoY, signalling Q4 acceleration after a sluggish first half.
Decorative paints India (~84% of consolidated revenue) remains the primary driver; international business (+8.9% YoY to ₹3,340 Cr) added meaningful incremental contribution.
Other income jumped 26.4% YoY (₹573 Cr → ₹724 Cr), partly cushioning operating pressure — a non-trivial ₹724 Cr on a ₹35,584 Cr revenue base.

Bottomline

Reported PAT rose 18.4% YoY (₹3,710 Cr → ₹4,395 Cr FY26); Q4 PAT up 69.3% YoY (₹701 Cr → ₹1,185 Cr), aided by the base effect of ₹183 Cr exceptional items in Q4FY25.
Exceptional items (₹158 Cr in FY26 vs. ₹365 Cr in FY25) largely impairments on international/home décor subsidiaries — lower drag this year inflates apparent YoY PAT improvement.
Effective tax rate held steady at ~26.8% (FY26: ₹1,609 Cr on PBT ₹6,003 Cr vs. ~27.3% in FY25).

Margins

PBDIT margin expanded ~110 bps YoY (17.8% → 18.9% on net sales); raw material cost ratio improved — materials consumed fell from ₹15,794 Cr to ₹15,384 Cr despite ~5% revenue growth, implying meaningful gross margin recovery.
Net profit margin (PAT/Revenue from ops): 12.4% FY26 vs. 10.9% FY25 — a clean 150 bps expansion, driven by operating leverage and lower input costs.
Employee costs (+7.8% YoY) and other expenses (+5.2% YoY) grew broadly in line with revenue — cost discipline holding.

Growth Trajectory

FY26 topline growth (5.0%) is the slowest in several years — volume-led growth story partially stalled amid competitive intensity from Birla Opus and muted urban demand.
Q4 re-acceleration (+10.6% revenue, +24.4% PBDIT) is encouraging but must sustain through H1FY27 to confirm a structural recovery rather than base-effect rebound.
Home décor (Kitchen + Bath) remains loss-making at PBIT level (combined ~₹19 Cr loss in FY26 vs. ~₹51 Cr in FY25) — improvement trajectory present but dilutive to consolidated ROCE.

GLENMARK – Glenmark Pharmaceuticals – Q4 FY26 Financial Results – 29-May-26

Glenmark’s FY26 marks inflection — debt‑free, doubled pre‑exceptional profitability, and robust OCF. Risks: +48.5% receivables surge and ₹22,661M exceptional charges cloud earnings quality. If receivables normalize and charges stabilize, ~₹20,873M FCF supports re‑rating; monitor DSO trends, exceptional disclosures, and ₹15,361M non‑current liability build.

1–2 minutes

🔍 Observations

Topline

Net sales surged 27.1% YoY (₹131,458M → ₹167,114M), driven by broad-based geographic expansion and the Ichnos Sciences consolidation effect post-demerger.
Q4FY26 net sales of ₹37,603M grew 16.8% YoY vs Q4FY25’s ₹32,201M, though sequentially softer vs Q3FY26’s ₹38,880M — slight volume moderation at year-end.
Other operating income jumped to ₹2,711M in FY26 vs ₹1,759M in FY25, reflecting licensing/milestone receipts boosting reported revenue quality.

Bottomline

Reported PAT: ₹13,620M in FY26 vs ₹10,471M in FY25 (+30.1% YoY), but exceptional losses of ₹22,661M (vs ₹3,728M prior year) dominate the narrative — pre-exceptional PBT was ₹42,508M vs ₹17,720M (+139.9% YoY), a far stronger underlying picture.
Q4FY26 PAT of ₹3,013M was inflated by negative current tax (refund of ₹301M) — normalized earnings were lower; Q3FY26 PAT of ₹4,032M was cleaner.
Basic EPS: ₹48.26 in FY26 vs ₹37.11 in FY25 — EPS growth understates operational improvement given the drag from escalating exceptional charges.

Margins

EBITDA proxy (pre-exceptional PBT + Finance costs + D&A): ₹42,508M + ₹2,087M + ₹5,735M = ₹50,330M on revenue of ₹169,825M → EBITDA margin ~29.6% in FY26 vs (₹17,720M + ₹2,071M + ₹4,860M) = ₹24,651M on ₹133,217M → 18.5% in FY25. A 1,110 bps margin expansion.
Reported net margin: ₹13,620M / ₹169,825M = 8.0% — depressed by exceptional items; pre-exceptional PBT margin = 25.0%.
Cost of materials + stock-in-trade consumed ₹47,475M (net of inventory changes ₹6,106M) = ₹41,369M effective material cost on ₹167,114M net sales = 24.8% — improved from prior year’s effective ~32.7%.

Growth Trajectory

Revenue CAGR implied (FY25→FY26): +27.1% — sustainable pace uncertain; Ichnos consolidation is a one-time step-up in the base.
Employee costs grew 18.4% YoY (₹30,221M → ₹35,779M) — below revenue growth, indicating early operating leverage.
Other expenses grew 13.6% YoY (₹35,950M → ₹40,848M) — again below revenue growth, reinforcing operating leverage thesis.

BEML – Beml Ltd – Q4 FY26 Financial Results – 29-May-26

BEML’s FY26 shows earnings compression — PAT down >50% on margin erosion, doubled provisions, and ballooning receivables despite revenue growth. CWIP tripling and Metro/Defence/Railways pipeline support thesis, but re‑rating hinges on expense normalization, receivables conversion, and provision reversal. Until OCF/FCF turn positive, execution visibility drives valuation.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 8.2% YoY (₹4,02,222L → ₹4,35,053L), modest but consistent; Q4FY26 at ₹1,79,417L surged 8.6% over Q4FY25, confirming H2-heavy execution pattern
Q3FY26 revenue of ₹1,08,327L was unusually weak — sequential collapse of ~40% — pointing to lumpy government order-driven recognition
Other income rose 24% YoY (₹2,373L → ₹2,944L), marginal contributor but directionally positive

Bottomline

FY26 PAT collapsed 51.7% YoY (₹29,252L → ₹14,136L) despite 8.2% revenue growth — a sharp earnings-quality deterioration
Q3FY26 posted a PAT loss of ₹2,238L; Q4FY26 recovered to ₹17,982L, but Q4FY25 PAT was ₹28,755L — Q4 profitability down 37.5% YoY
Effective tax rate distorted by large deferred tax credit of ₹6,965L in FY26 vs. ₹1,161L charge in FY25; underlying cash tax burden (₹12,725L) stayed elevated

Margins

FY26 EBITDA (PBT + Finance Costs + D&A): ₹19,956 + ₹4,539 + ₹8,348 = ₹32,843L on revenue of ₹4,35,053L → EBITDA margin ~7.5%, down from ~13.1% in FY25 (₹40,376 + ₹5,431 + ₹7,134 = ₹52,941L on ₹4,02,222L)
Net margin compressed to 3.2% (₹14,136L / ₹4,35,053L) vs. 7.3% in FY25 — a 410bps contraction
Other expenses surged 38.8% YoY (₹67,558L → ₹93,787L) on only 8.2% revenue growth — the single largest margin erosion driver

Growth Trajectory

Revenue CAGR is low-single-digit; at current trajectory BEML is not a high-growth compounder but an order-execution vehicle dependent on government capex cycles
Provisions rose sharply: current provisions jumped from ₹25,870L to ₹53,259L (+105.9%), signalling warranty, contractual, or contingent liability build-up
Non-current liabilities grew 8.4% (₹1,11,816L → ₹1,21,178L) while equity grew just 1.6% — leverage creeping up structurally

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Earnings Call – 22-May-26

Max Healthcare’s topline growth hinges on non-onco scaling and greenfield execution, while margins face structural pressure from oncology mix shifts and ALOS volatility.

1–2 minutes

Also see: MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Oncology share stabilizes at 21–22% + Gurgaon breakeven in FY28.
Revenue grows 12–15% CAGR (ex-oncology: 15–18%) as digital/international offset oncology drag. EBITDA margins hover at 26–27% due to ALOS/labor cost lags. Free cash flow ~₹1,500 crore/year funds ₹1,200–1,500 crore annual capex, keeping net debt-to-EBITDA <1.2x.

SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Earnings Call – 22-May-26

Sun Pharmaceutical Industries’ topline growth hinges on Innovative Medicines and Organon synergies, while margins and EPS are sensitive to cost normalization, tax rates, and execution risks.

1–2 minutes

Also see: SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Financial Results – 22-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Organon integration on track (Q4 FY27), Innovative Medicines growth (15–20% YoY), margin stabilization (27–28% EBITDA).
Outcome: High single-digit topline growth achieved, EPS stable with tax rate at 25%, generics recovery lagging but offset by Innovative Medicines. Semaglutide gains traction in H2 FY27.

PAGEIND – Page Industries – Q4 FY26 Earnings Call – 21-May-26

Page Industries’ topline growth hinges on volume momentum and premiumization, while margins face structural pressure from input costs and marketing spend, with EBITDA likely normalizing to 19–21%.

1–2 minutes

Also see: PAGEIND – Page Industries – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Stable macro, moderate input inflation, sustained premiumization.
Revenue grows 10–12% YoY (volume-led), with EBITDA margins at 20–21% (marketing spend ~5%, partial cost pass-through). E-commerce share rises to 16–17%, offsetting offline softness. Subsidies (INR 40–50 crore) support cash flow. Implication: *Topline resilience, margin stability, but limited upside.

FINCABLES – Finolex Cables – Q4 FY26 Financial Results – 28-May-26

Finolex Cables’ FY26 delivered 18.8% revenue growth but just 1.8% PAT, with WC build in inventories/receivables crushing cash generation. Communication Cables show early margin recovery, but re‑rating hinges on FY27 WC normalization as copper cycle turns and collections catch up — shifting from value to cash compounder.

1–2 minutes

🔍 Observations

Topline

Revenue surged 18.8% YoY (₹5,319 Cr → ₹6,321 Cr), with Q4 FY26 alone up 22.3% QoQ (₹1,599 Cr → ₹1,951 Cr) — strongest quarter of the year.
Electrical Cables drove the bulk, contributing ₹5,490 Cr (86.9% of net revenue), up 22.0% YoY; Communication Cables marginally declined to ₹500 Cr from ₹508 Cr.
Copper Rods segment grew 27.2% YoY (₹1,684 Cr → ₹2,143 Cr) but is largely inter-segment; net contribution post eliminations is modest.

Bottomline

PAT grew a thin 1.8% YoY (₹701 Cr → ₹714 Cr) despite 18.8% topline growth — muted profit leverage driven by cost absorption.
Associate/JV income fell 11.8% YoY (₹232 Cr → ₹205 Cr), reducing an important non-operating cushion; Q4 FY26 associate income of ₹107 Cr (vs ₹49 Cr in Q4 FY25) was an outlier quarter.
Tax efficiency improved: effective tax rate fell to 23.1% in FY26 vs 24.0% in FY25, providing marginal PAT support.

Margins

EBIT margin (segment EBIT ÷ net revenue): FY26 = ₹583 Cr ÷ ₹6,321 Cr = 9.2% vs FY25 = ₹492 Cr ÷ ₹5,319 Cr = 9.2% — flat YoY despite scale.
PAT margin compressed: FY26 = ₹714 Cr ÷ ₹6,321 Cr = 11.3% vs FY25 = ₹701 Cr ÷ ₹5,319 Cr = 13.2% — 190 bps dilution as associate income share in total profits declined proportionally.
Material cost ratio rose: FY26 cost of materials consumed = ₹5,328 Cr on ₹6,321 Cr revenue = 84.3% vs FY25 ₹4,360 Cr on ₹5,319 Cr = 82.0% — input cost pass-through pressure evident.

Growth Trajectory

Electrical Cables EBIT grew 18.3% YoY (₹476 Cr → ₹563 Cr), in line with revenue — segment-level margins held.
Communication Cables turned meaningfully profitable: EBIT ₹8.2 Cr (FY25) → ₹13.9 Cr (FY26), a 69.8% jump on flat revenue — operating leverage kicking in.
Copper Rods EBIT declined (₹4.4 Cr → ₹3.2 Cr) on higher revenues — margin dilution at the commodity pass-through segment, as expected.

DIVISLAB – Divi’s Laboratories – Q4 FY26 Earnings Call – 23-May-26

DIVISLAB/ Divi’s Laboratories’ topline growth remains robust (double-digit) on volume resilience and CS pipeline, but margins are structurally capped (~32%) by pricing pressure and cost inflation; bottomline stability hinges on forex and capex efficiency.

1–2 minutes

Also see: DIVISLAB – Divi’s Laboratories – Q4 FY26 Financial Results – 23-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Double-digit revenue growth sustained via volume stability in generics and gradual CS ramp-up. Margins remain flat at ~32% as RM/freight pressures offset INR benefits. Capex conversion cycle averages 2 years; FY27 capex at ~₹2,000 crores (18% of sales). Forex gains neutralize due to hedging.

APARINDS – Apar Industries – Q4 FY26 Financial Results – 28-May-26

Apar Industries’ FY26 confirms volume‑led growth in Conductors/Cables, but ₹1,867 Cr WC build compressed OCF. Re‑rating hinges on FY27 receivables recovery and FCF re‑expansion; margin watch: 30 bps segment compression and 60% unallocable cost spike. Capacity‑constrained compounder — monitor DSO trends and CWIP activation quarterly.

1–2 minutes

🔍 Observations

Topline

Revenue from Operations jumped 23.3% YoY (₹18,581 Cr → ₹22,902 Cr), with Q4FY26 alone clocking ₹6,603 Cr — the strongest quarter of the year, up 26.7% YoY.
Conductors dominated at ₹12,712 Cr (55% of segment revenue), growing 32.7% YoY; Cables surged 25.8% YoY to ₹6,220 Cr — both segments accelerating meaningfully.
Transformer & Speciality Oils grew a modest 5.6% YoY to ₹5,373 Cr, acting as the revenue drag relative to peer segments.

Bottomline

PAT grew 18.9% YoY (₹821 Cr → ₹977 Cr); EPS rose from ₹204.47 to ₹243.21 — a clean, unlevered earnings expansion.
Exceptional items of ₹32.53 Cr (net charge) dented reported PBT in FY26; pre-exceptional PBT grew 21.4% YoY (₹1,106 Cr → ₹1,342 Cr), a more accurate read of operating performance.
Q4FY26 PAT of ₹253 Cr was flattish YoY (vs. ₹250 Cr in Q4FY25) despite a 27% revenue jump — margin compression at the quarterly level warrants watching.

Margins

Segment EBIT margin (Total Segment Results / Total Segment Revenue): FY26 = ₹1,968 Cr / ₹24,501 Cr = 8.0% vs. FY25 = ₹1,634 Cr / ₹19,757 Cr = 8.3% — a 30 bps compression despite absolute profit growth.
Net profit margin contracted slightly: FY26 = ₹977 Cr / ₹22,902 Cr = 4.27% vs. FY25 = ₹821 Cr / ₹18,581 Cr = 4.42% — scale is outrunning margin expansion.
Unallocable expenses ballooned 60.6% YoY (₹117 Cr → ₹189 Cr), the primary margin headwind at the PBT level.

Growth Trajectory

3-year revenue CAGR implied from FY25→FY26 base is strong; the 23% single-year step-up on an already ₹18,581 Cr base signals Apar is capturing the T&D capex upcycle, not just riding it.
Cables segment re-rating underway — grew from ₹4,945 Cr to ₹6,220 Cr (+25.8%) with EBIT jumping 29.5% (₹459 Cr → ₹595 Cr), margin holding near 9.6%.
Conductor EBIT grew 21.9% YoY on 32.7% revenue growth, implying mild margin dilution — likely mix/pricing pressure as volumes scale into commodity-linked orders.

CUMMINSIND – Cummins India – Q4 FY26 Financial Results – 27-May-26

Cummins India’s FY26 delivered 17% revenue and 18% PAT growth, debt‑free balance sheet, and ₹1,400 Cr FCF with ~160 bps margin expansion. Risks: ₹477 Cr receivables build and ₹503 Cr WC drag compressing FCF conversion. Strong industrial capex visibility, but sustaining premium valuations hinges on FCF quality.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.9% YoY (₹10,219 Cr → ₹11,950 Cr), driven entirely by the Engines segment — the sole reported business post-Lubes elimination.
Q4FY26 revenue at ₹2,963 Cr grew 22.1% YoY vs Q4FY25 (₹2,428 Cr), but dipped 1.4% QoQ from Q3’s ₹3,006 Cr — minor sequential softness.
Other income (₹517 Cr in FY26 vs ₹447 Cr in FY25) contributes meaningfully to reported profits; treasury income of ₹189 Cr is the primary driver.

Bottomline

Reported PAT grew 18.1% YoY (₹2,000 Cr → ₹2,362 Cr); adjusting for net exceptional charges of ₹82 Cr (FY26) vs nil (FY25), underlying PAT growth is closer to 22%.
Q4FY26 PAT at ₹649 Cr grew 22.7% YoY (vs ₹530 Cr in Q4FY25) and 33.6% QoQ — the Q3 base was depressed by ₹127 Cr labour code provision.
JV/associate profit contribution (Valvoline Cummins) held flat at ₹266 Cr YoY — no incremental earnings growth from this portfolio.

Margins

Operating margin (EBIT, pre-other income): Profit before exceptional items = ₹2,901 Cr on revenues of ₹11,950 Cr. Stripping other income (₹517 Cr) yields core EBIT of ~₹2,384 Cr on ₹11,950 Cr = ~20.0% core operating margin vs ~18.4% in FY25 (₹1,879 Cr / ₹10,219 Cr) — ~160 bps expansion YoY.
Net profit margin: ₹2,362 Cr / ₹11,950 Cr = 19.8% (FY26) vs ₹2,000 Cr / ₹10,219 Cr = 19.6% (FY25) — marginal expansion, as tax rate and exceptional items offset operating gains.
Employee costs declined slightly (₹797 Cr → ₹794 Cr) despite revenue growing 17% — meaningful operating leverage on the fixed-cost base.

Growth Trajectory

Three-year demand cycle in industrial/power generation engines remains intact; 17% topline growth on a ₹10,000 Cr+ base signals broad-based volume + mix improvement.
Lubes segment (Valvoline Cummins, 100% consolidated in segment but eliminated at group level) grew revenue 28% YoY (₹2,352 Cr → ₹3,009 Cr) — outpacing Engines; margin recovery notable.
Free cash flow (OCF ₹1,734 Cr less capex ₹252 Cr) = ₹1,482 Cr in FY26 vs ₹1,457 Cr in FY25 — FCF growth nearly flat despite 18% PAT growth, due to working capital absorption.